Effect of Chemotherapy on PD-L1 in NSCLC

Status Recruiting

Clinical Trial Summary

PD-L1 is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune reaction. However, it remains unclear whether chemotherapy could affect PD-L1 in advanced NSCLC patients. The present study aims to evaluate whether PD-L1 will change after receiving chemotherapy in advanced NSCLC patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03701607
Study type	Observational
Source	Shanghai Changzheng Hospital
Contact
Status	Recruiting
Phase
Start date	September 1, 2018
Completion date	August 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05848011` - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Phase 2
Recruiting	`NCT05161572` - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer	Phase 2
Recruiting	`NCT06165900` - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC	Phase 2
Recruiting	`NCT06120127` - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence	Phase 2
Recruiting	`NCT06262581` - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery	Phase 2
Recruiting	`NCT05176002` - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.	Phase 1/Phase 2
Not yet recruiting	`NCT05909137` - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting	`NCT04500990` - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting	`NCT04372732` - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed	`NCT02692976` - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients	Phase 2
Completed	`NCT03763630` - MAPS & ITEC Cohorts: 6-8 Years Follow-up	Phase 2
Not yet recruiting	`NCT06012318` - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting	`NCT05479240` - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer	Phase 2
Recruiting	`NCT05515796` - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	Phase 2
Recruiting	`NCT04711330` - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting	`NCT03683407` - Effect of Chemotherapy on TMB in NSCLC
Completed	`NCT03357861` - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting	`NCT05223088` - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer	Phase 2
Completed	`NCT05657262` - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas	N/A
Recruiting	`NCT05621356` - Monitoring Allergen Immunotherapy in Allergic Rhinitis